naa a22 4500 510764118 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s12094-013-1018-0 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1018-0 Molecular biomarkers in the decision of treatment of cervical carcinoma patients [Elektronische Daten] [A. Valenciano, L. Henríquez-Hernández, M. Lloret, B. Pinar, P. Lara] Cervical carcinoma is the third most common cancer in women worldwide. The programs developed for early detection have made that most patients are diagnosed in early stages. Treatment for those patients consists of conservative techniques as surgery or radical radiotherapy; however, the decision between those two therapies is still controversial. Even though in many cases this decision varies according to classical associated risk factors (i.e. tumor stage or age), in the clinical practice, a significant number of patients treated by surgery also receive post-surgery radiotherapy, with the consequent over-treatment and toxic effects. Since response to treatments is conditioned by individual factors, the use of new biological markers as novel predictive factors for both tumor and normal tissues could help clinicians to choose the best treatment schedule for each patient individually. Based on the experience of our institution, we have reviewed the new biological markers in cervical carcinoma patients treated by radiotherapy. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Cervical cancer nationallicence Biological markers nationallicence Prognostic factors nationallicence Radiotherapy nationallicence Radiation-induced toxicity nationallicence Valenciano A. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut Henríquez-Hernández L. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut Lloret M. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut Pinar B. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut Lara P. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 587-592 1699-048X 15:8<587 2013 15 12094 https://doi.org/10.1007/s12094-013-1018-0 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1018-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Valenciano A. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut NATIONALLICENCE 700 1- Henríquez-Hernández L. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut NATIONALLICENCE 700 1- Lloret M. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut NATIONALLICENCE 700 1- Pinar B. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut NATIONALLICENCE 700 1- Lara P. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 587-592 1699-048X 15:8<587 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer